These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27157188)

  • 1. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
    Bompiani KM; Tsai CY; Achatz FP; Liebig JK; Howell SB
    Metallomics; 2016 Sep; 8(9):951-62. PubMed ID: 27157188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
    Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB
    J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
    Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
    Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
    Blair BG; Larson CA; Safaei R; Howell SB
    Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
    Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
    Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distorted copper homeostasis with decreased sensitivity to cisplatin upon chaperone Atox1 deletion in Drosophila.
    Hua H; Günther V; Georgiev O; Schaffner W
    Biometals; 2011 Jun; 24(3):445-53. PubMed ID: 21465178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
    Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
    Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
    Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
    Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
    Abada PB; Larson CA; Manorek G; Adams P; Howell SB
    Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Jaehde U
    J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake.
    Lv X; Song J; Xue K; Li Z; Li M; Zahid D; Cao H; Wang L; Song W; Ma T; Gu J; Li W
    Mol Carcinog; 2019 May; 58(5):794-807. PubMed ID: 30614075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).
    Tsai CY; Liebig JK; Tsigelny IF; Howell SB
    Metallomics; 2015 Nov; 7(11):1477-87. PubMed ID: 26205368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
    Wang X; Jiang P; Wang P; Yang CS; Wang X; Feng Q
    PLoS One; 2015; 10(4):e0125402. PubMed ID: 25927922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P; Wu X; Wang X; Huang W; Feng Q
    Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
    Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
    Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene duplication and neo-functionalization in the evolutionary and functional divergence of the metazoan copper transporters Ctr1 and Ctr2.
    Logeman BL; Wood LK; Lee J; Thiele DJ
    J Biol Chem; 2017 Jul; 292(27):11531-11546. PubMed ID: 28507097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.